Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (ARNA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
arna · stock forecast · 23 analysts (3M) · FMP · updated Dec 4, 2023
Analyst Rating & Consensus
Based on 23 Wall Street analysts in the past 3 months
Buy
23 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$100
Consensus
$94.00
-6.0% upside
Low
$90.00
Median: $92 · Last Close: $99.99
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$94.00
-6.0% upside
High Target
$100
0.0%
Low Target
$90
-10.0%
Current Price
$99.99
as of today
Based on analyst price targets, the ARNA stock price prediction for the next 12 months ranges from $90 to $100. The consensus ARNA price forecast of $94.00 implies -6.0% upside from the current price of $99.99.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $101.36 | ↑ 1.37% |
1-day model range: $101.14–$101.58. Peak: $101.58 (+1.37%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ARNA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-02-09 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2021-12-21 | Cantor Fitzgerald | Downgrade ↓ | Overweight→Neutral |
| 2021-12-14 | RBC Capital | Downgrade ↓ | Outperform→Perform |
| 2021-12-14 | SVB Leerink | Downgrade ↓ | Outperform→Perform |
| 2021-12-14 | JMP Securities | Downgrade ↓ | Market Outperform→Perform |
| 2021-12-14 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2021-08-10 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2021-08-06 | Credit Suisse | Maintains | Outperform→Outperform |
| 2021-05-18 | Goldman Sachs | Maintains | Buy→Buy |
| 2021-05-07 | SVB Leerink | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Arena Pharmaceuticals, Inc. (ARNA) stock. Of the recent 64 rating actions, 4 were upgrades and 7 were downgrades. 23 analysts currently cover ARNA.
Analyst Recommendation Trends
ARNA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast ARNA EPS of $— for the current fiscal year, based on estimates from 0 analysts. The ARNA revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ARNA stock forecast is supported by two independent data sources: analyst consensus ratings from 23 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ARNA price target is $94.00 (-6.0% upside), with an analyst consensus of Buy.
The ARNA short-term stock prediction for tomorrow is $101.36 (+1.37%).
Arena Pharmaceuticals, Inc. trades on NASDAQ under the ticker ARNA. The ARNA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 61% of covering analysts.
Frequently asked questions
ARNA forecast · 8 questionsAccording to 23 Wall Street analysts, the average 12-month ARNA price target is $94.00, with a high forecast of $100.00 and a low of $90.00. The median price target is shown in the chart above when available. This implies -6.0% potential upside from the current price of $99.99.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.